Axel Hoos, M.D., Ph.D. of GlaxoSmithKline discusses the ATOM Initiative.
BY Axel Hoos, M.D., Ph.D.
PUBLISHED July 06, 2017
Axel Hoos, M.D., Ph.D., Head of Oncology of GlaxoSmithKline (GSK), discusses the ATOM Initiative.
Joining with the Department of Energy and the National Cancer Insitute, GSK is working on in silico screening. The ATOM Initiative uses a super-computer, owned by the Department of Energy to rapidly identify potential new pharmacuetical agents to target cancer. This super-computer can screen the compounds much faster than any other computer that exists. This initiative is still in the pilot stage as it is a completely novel concept.